Tag Archive for: radioligand therapy
Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Clinical Trial: 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxVIOLET Phase 1/2 Trial Final Results: 161Tb-PSMA-I&T Shows Promising Results
/in Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial of Novel Radioligand Therapy 177Lu-JH020002 Shows Promise
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by Max225Ac-Macropa-PEG4-YS5: a CD46-Targeted 225Ac Therapy for Prostate Cancer
/in Preclinical Research/by MaxUpdate: FC705 Signals a Leap Forward in Prostate Cancer Therapy, Outperforming Pluvicto
/in Clinical Trial, Metastatic, Phase 2/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Biallelic Loss in DDR Genes and Its Clinical Impact July 25, 2026
- How DNA “Switches” in Prostate Cancer May Open New Treatment Paths July 25, 2026
- UPDATE: VIR-5500 Extended into mHSPC July 24, 2026
- UPDATE: SL-28 Phase 1/2 Trial Started To Recruit in Advanced Solid Tumors July 23, 2026